{"nctId":"NCT02541383","briefTitle":"A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma","startDateStruct":{"date":"2015-09","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"count":1085,"armGroups":[{"label":"Arm A Part 1","type":"OTHER","interventionNames":["Drug: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)"]},{"label":"Arm B Part 1","type":"EXPERIMENTAL","interventionNames":["Drug: Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab"]},{"label":"Arm A Part 2","type":"NO_INTERVENTION","interventionNames":[]},{"label":"Arm B Part 2","type":"EXPERIMENTAL","interventionNames":["Drug: Daratumumab"]}],"interventions":[{"name":"Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)","otherNames":["Arm A Part 1"]},{"name":"Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab","otherNames":["Arm B Part 1"]},{"name":"Daratumumab","otherNames":["Arm B Part 2"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of previously untreated multiple myeloma (MM)\n* Have a confirmed diagnosis and eligible for high dose chemotherapy and autologous stem cell transplantation, and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0,1 or 2\n\nExclusion Criteria:\n\n* previous treatment for Multiple Myeloma\n* Primary amyloidosis, Plasma Cell Leukemia or Smoldering Multiple Myeloma\n* Prior or concurrent exposure to systemic therapy or SCT (Stem Cell Transplantation) for any plasma cell dyscrasia, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before treatment, or received an investigational drug or used an invasive investigational medical device within 4 weeks before Cycle 1, Day 1\n* history of malignancy (other than Multiple Myeloma) within 10 years before the date of randomization, except for the following if treated and not active: basal cell or nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of breast, or International Federation of Gynecology and Obstetrics (FIGO) Stage 1 carcinoma of the cervix\n* known chronic obstructive pulmonary disease (COPD) or moderate to severe asthma\n* any concurrent medical or psychiatric condition or disease (eg, autoimmune disease, active systemic disease, myelodysplasia) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Post-Consolidation Stringent Complete Response (sCR) Rate","description":"Post-consolidation sCR rate is defined as the percentage of ITT subjects who achieved or maintained sCR status within 30 days of Day 100 post Autologous Stem Cell Transplant (ASCT). The sCR status is assessed using the computerized algorithm according to IMWG response criteria, and must be achieved on or prior to start of subsequent therapies. Subjects must not die or progress by Day 100 post ASCT.\n\nAccording to the IMWG consensus recommendations for multiple myeloma treatment response criteria from 2006, the stringent complete response (sCR) was defined by a negative immunofixation on the serum and urine, and a disappearance of any soft tissue plasmacytomas, and \\< 5% plasma cells in bone marrow, plus normal free-light chain ratio and the absence of clonal bone marrow plasma cells by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"157","spread":null}]}]}]},{"type":"PRIMARY","title":"Progression Free Survival (PFS) Post Completion of Maintenance Therapy","description":"Progression Free Survival (PFS) post completion of maintenance therapy is defined as the duration from the date of second randomization to either progressive disease (according to the IMWG criteria specified in the protocol), or death, whichever occurs first (=all these considered as events) at the completion of Maintenance therapy.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) From First Randomization up to the End of the Study","description":"Progression Free Survival (PFS) is defined as the duration from the date of first randomization to either progressive disease (according to the IMWG criteria specified in the protocol), or death, whichever occurs first (=all these considered as events) at the end of the study","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.8","spread":null},{"groupId":"OG001","value":"83.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":261,"n":538},"commonTop":["Peripheral Sensory Neuropathy","Constipation","Bronchitis","Asthenia","Oedema Peripheral"]}}}